Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the ESSENCE study

被引:3
|
作者
Nasonov, E. [1 ]
Soloviev, S. [1 ]
Davidson, J. E. [2 ]
Lila, A. [3 ]
Togizbayev, G. [4 ]
Ivanova, R. [5 ]
Baimukhamedov, Ch [4 ]
Omarbekova, Zh [4 ]
Laremenko, O. [6 ]
Gnylorybov, A. [7 ]
Shevchuk, S. [8 ]
Vasylyev, A. [9 ]
Makarova, J. [10 ]
Tariq, L. [11 ]
机构
[1] Russian Acad Med Sci, Inst Rheumatol, Moscow, Russia
[2] GlaxoSmithKline R&D, Worldwide Epidemiol, Stockley Pk, Uxbridge, Middx, England
[3] North Western Med Univ, St Petersburg, Russia
[4] Inst Adv Educ Asyl Clin, Alma Ata, Kazakhstan
[5] Semey State Med Univ, Internal Med Dept, Semey, Kazakhstan
[6] Natl Med Univ, Kiev, Ukraine
[7] Natl Acad Med Sci Ukraine, Inst Urgent & Recovery Surg, Kiev, Ukraine
[8] Vinnytsya Natl Med Univ, Sci Res Inst Rehabil Disabled, Vinnitsya, Ukraine
[9] GlaxoSmithKline, Kiev, Ukraine
[10] GlaxoSmithKline, Moscow, Russia
[11] GlaxoSmithKline, Dubai, U Arab Emirates
关键词
Systemic Lupus Erythematosus; SLE; healthcare resource consumption; Russia; Kazakhstan; Ukraine; COSTS; SLE; NEPHRITIS; COUNTRIES; ETHNICITY; IMPACT;
D O I
10.1080/13696998.2018.1499518
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: To evaluate healthcare resource (HR) consumption associated with Systemic Lupus Erythematosus (SLE) management in adult patients with active autoantibody positive disease in the Russian Federation, Republic of Kazakhstan, and Ukraine. Methods: The ESSENCE was a retrospective, observational study, and included data on patients' clinical characteristics and SLE-related HR use (laboratory, biopsy, imaging tests, medications, visits to specialists, outpatient visits, hospitalizations) during 2010 from the 12 specialized rheumatologic centers. Results: A total of 436 SLE patients were included in the analyses, with 232 patients being enrolled in Russia, 110 in Kazakhstan, and 94 in Ukraine. The mean age was 36-42 years and median SLE duration was 3-6.8 years across the countries. Extrapolation to total country population showed that, in 2010, visits to specialists (who assign treatment for organs involved/damaged by SLE) were the most frequently used HR (from 13,439 visits in Kazakhstan to 23,510 in Russia), followed by hospitalizations (from 2,950 in Kazakhstan to 6,267 in Russia) and outpatient visits (from 1,654 visits in Russia to 8,064 in Kazakhstan). Compared to chronic active patients (SLE persistent during last year), patients with relapsing-remitting SLE (at least one flare alternated by one remission per year) had a higher rate of visits to specialists (100% vs 60.8%, p < .001) and hospitalizations (98.9% vs 60.8%, p < .001). Compared to patients without flares, patients experiencing flares had a higher rate of unplanned visits to specialists (86.2% vs 6.3%, p < .001), were more often hospitalized (both ICU and non-ICU) (100.0% vs 50.0%, p < .001), and had a longer duration of ICU hospitalization (25.9 days vs 17.5 days, p < .001). Conclusions: Specialist visits are the most frequently consumed SLE-related healthcare recourse in the Commonwealth of Independent States (CIS) countries. A relapsing-remitting SLE profile and the occurrence of flares significantly raise healthcare resource consumption.
引用
收藏
页码:1006 / 1015
页数:10
相关论文
共 37 条
  • [21] Experience with macrophage activation syndrome associated with systemic lupus erythematosus: A single-center study from Pakistan
    Khan, Saira Elaine Anwer
    Shamim, Roshila
    Khan, Asadullah
    Batool, Shabnam
    Aslam, Muhammad Zeeshan
    INDIAN JOURNAL OF RHEUMATOLOGY, 2022, 17 (02) : 118 - 123
  • [22] Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
    Mehta, Pankti
    Srivastava, Akansha
    Aggarwal, Amita
    Rajasekhar, Liza
    Shobha, Vineetha
    Kavadichanda, Chengappa
    Mathew, Ashish Jacob
    Ghosh, Parasar
    Das, Bidyut
    Jain, Avinash
    Gupta, Ranjan
    Rathi, Manish
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2851 - 2853
  • [23] Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study
    Cortes-Hernandez, Josefina
    Marras Fernandez-Cid, Carlos
    Andreu Sanchez, Jose Luis
    Calvo Alen, Jaime
    Garcia-Aparicio, Angel M.
    Diez Alvarez, Elvira
    Hidalgo Bermejo, Francisco Javier
    Coronell, Carlos
    Perna, Alessandra
    Ordi Ros, Josep
    REUMATOLOGIA CLINICA, 2023, 19 (06): : 312 - 318
  • [24] Healthcare Costs Associated with Systemic Lupus Erythematosus (SLE) in the Year Prior to Diagnosis of ESKD: Real-World Evidence from Two Databases in the United States
    Bell, Christopher F.
    Huang, Shirley
    Guisinger, Amy
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 738 - 738
  • [25] Ant -Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study
    Choe, Jung-Yoon
    Lee, Shin-Seok
    Kwak, Sang Gyu
    Kim, Seong-Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (21)
  • [26] ASSOCIATED FACTORS AND PREVALENCE OF OSTEONECROSIS IN A COHORT STUDY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FROM HOSPITAL DEL MAR/PARC DE SALUT MAR
    Vilchez-Oya, Francisco
    Antonio Meraz-Ostiz, Juan
    Carrion Barbera, Irene
    Labrada, Selene
    Castell, Sonia
    Salman Monte, Tarek Carlos
    Ojeda, Fabiola
    Rodriguez, Eva
    Duran, Rodriguez
    Perez-Garcia, Carolina
    Monfort, Jordi
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1741 - 1742
  • [27] Systemic Lupus Erythematosus is Associated With Higher In-hospital Mortality Among Patients Hospitalized With Heart Failure: Findings From a United States National Study
    Mazumder, Nabila K.
    Mujib, Marjan
    Aronow, Wilbert S.
    Gupta, Tanush
    Paul, Neha
    Kolte, Dhaval
    Khera, Sahil
    Harikrishnan, Prakash
    Palaniswamy, Chandrasekar
    Sule, Sachin
    Ahmed, Ali
    Frishman, William H.
    Jain, Diwakar
    Cooper, Howard A.
    Fonarow, Gregg C.
    Panza, Julio A.
    CIRCULATION, 2015, 132
  • [28] SLE-DAS AS AN ALTERNATIVE TOOL TO MEASURE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON WITH SLEDAI-2K, IN A POPULATION FROM THE DOMINICAN REPUBLIC. PILOT STUDY
    Perez Rodriguez, L.
    Alvarez Santana, R. A.
    Garcia, D.
    Polanco Mora, T.
    Concepcion Sanchez, L.
    Paulino, I.
    Mercedes, I.
    Rodriguez Bautista, E.
    Valdez, T.
    Feriz, A.
    Munoz Louis, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 814 - 814
  • [29] Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center
    Melissa Padovan
    Gabriella Castellino
    Alessandra Bortoluzzi
    Luisa Caniatti
    Francesco Trotta
    Marcello Govoni
    Rheumatology International, 2012, 32 : 129 - 135
  • [30] IL-10RB rs2834167 (A/G) Polymorphism Is Associated with the Susceptibility to Systemic Lupus Erythematosus: Evidence from a Study in Chinese Han Population
    Peng, Hui
    Liu, Cai-Yun
    Zhou, Mo
    Wen, Peng-Fei
    Zhang, Min
    Qiu, Li-Juan
    Ni, Jing
    Liang, Yan
    Pan, Hai-Feng
    Ye, Dong-Qing
    INFLAMMATION, 2013, 36 (06) : 1218 - 1224